BeStock  
Stocks › Biotechnology › ACRS

Aclaris Therapeutics ACRS

US equityMarket cap rank #3745Biotechnology
$3.40 −$0.30 (-8.11%)
Pre-market · Oct 8, 9:10 am ET · After hours $3.46 +1.76%
Open$3.60
Prev close$3.70
Day range$3.32 – $3.62
Volume9.00M
Market cap$500.48M
P/E (TTM)–
Dividend yield–

ACRS Stock News

Headlines matching Aclaris Therapeutics or the ACRS ticker, most recent first.

  • CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10Market news · 1 Sep 2026 · Direct mention
  • Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10Market news · 6 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16Market news · 10 Aug 2026 · Direct mention
  • LifeSci Capital Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $13Market news · 2 Jun 2026 · Direct mention
  • Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10Market news · 9 May 2026 · Direct mention
  • Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10Market news · 8 May 2026 · Direct mention
  • Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12Market news · 5 May 2026 · Direct mention
  • Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 PositiveMarket news · 5 May 2026 · Direct mention
  • Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12Market news · 11 May 2026 · Direct mention
  • Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $10 PositiveMarket news · 29 Apr 2026 · Direct mention
  • Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10Market news · 16 Apr 2026 · Direct mention
  • Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11Market news · 7 Oct 2026 · Direct mention
  • LifeSci Capital Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $13Market news · 2 Oct 2026 · Direct mention
  • Craig-Hallum Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10Market news · 30 Jan 2026 · Direct mention
  • Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $8Market news · 14 Jan 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on ACRS.

Leave a comment

Scroll to Top